Preparation and characterization of solid lipid nanoparticles loaded with α-asarone

PDA Journal of Pharmaceutical Science and Technology

Volumn 62, Issue 1, 2008, Pages 56-65

  Wang, Dongkai ^a   Wang, Xiaoyan ^b   Li, Xiang ^a   Ye, Linmao ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Asarone; Bioavailability; Pharmacokinetics; Solid lipid nanoparticle (SLN); Tissue distribution

Indexed keywords

ALPHA ASARONE; INDOMETACIN; SOLID LIPID NANOPARTICLE; ANISOLE DERIVATIVE; ASARONE; FIBRINOLYTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ANALYSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG SYNTHESIS; MALE; MAXIMUM PLASMA CONCENTRATION; MORPHOLOGY; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PH; RAT; TISSUE DISTRIBUTION; VISCOSITY; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; BLOOD; CHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE ABSORPTION; TRANSMISSION ELECTRON MICROSCOPY; WISTAR RAT;

ANIMALS; ANISOLES; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FIBRINOLYTIC AGENTS; INTESTINAL ABSORPTION; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; PARTICLE SIZE; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 42449114085     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Heurtault, B.; Saulnier, P.; Pech, B.; Proust, J. E.; Benoit, J. P. Physico-chemical stability of colloidal lipid particles. Biomaterials 2003, 24, 4283-4300.
2. Müller, R. H.; Mader, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50, 161-177.
3. Müller, R. H.; Maaßen, S.; Weyhers, H.; Specht, F.; Lucks, J. S. Cytotoxicity of magnetite loaded polylactide, olylactide/glycolide particles and solid lipid nanoparticles (SLN). Int. J. Pharm. 1996, 138, 85-94.
4. Müller, R. H.; Rühl, D.; Runge, S. A. Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int. J. Pharm. 1996, 144, 115-121.
5. Cavalli, R.; Gasco, M. R.; Chetoni, P.; Burgalassi, S.; Saettone, M. F. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int. J. Pharm. 2002, 238, 241-245.
6. Yang, S. C.; Lu, L. F.; Cai, Y.; Zhu, J. B.; Liang, B. W.; Yang, C. Z. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Controlled Release 1999, 59, 299-307.
7. Olbrich, C.; Bakowsky, U.; Lehr, C. M.; Müller, R. H.; Kneuer, C. Cationic solid-lipid nano-particles can efficiently bind and transfect plasmid DNA. J. Controlled Release 2001, 77, 345-355.
8. Tong, G. Z.; Yang, Y. A review of α-Asarone. Jian Med. J. 1990, 12, 673-674.
9. Wu, C. A review of α-Asarone. Chin. Pharm. J. 1997, 32 (3), 129-132.
10. Yang, Z. H.; Wu, C. Study on the biovailability of α-Asarone in human body. Chin. Hosp. Pharm. J. 1997, 17 (4), 165-167.
11. Wu, C. Study on the bioavailability of Asarone tablets. Chin. Hosp. Pharm. J. 2003, 23 (10), 597-598.
12. Hu, L. D.; Tang, X.; Cui, F. D. Solid lipid nano-particles (SLNs) to improve oral bioavailability of poorly soluble drugs. Journal of Pharmacy and Pharmacology" J. Pharm. Pharmacol. 2004, 56, 1527-1535.
13. Liu, Z. H.; Li, D. R.; Yang, Y. Z. Determination of α-Asaricin concentration in human serum by HPLC. Chin. J. of Chromatography. 1994, 12, 74-75.
14. Hu, F. Q.; Yuan, H.; Zhang, H. H. Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int. J. Pharm. 2002, 239, 121-128.
15. Desai, M. P.; Labhasetwar, V.; Amidon, G. L.; Levy, R. J. Gastrointes-tinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 1996, 13, 1838-1845.
16. René, H.; Anette, M; Egon, C. Comparison of total oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rats. Eur. J. Pharm. Sci. 2001, 14 (4), 331-337.
17. Lana, D.; Gillian, A. Nicotine and behavioral markers of risk for schizophrenia: A double-blind, placebo-controlled, cross-over study. Neuropsychopharmacology 2002, 27 (6), 1056-1070.
18. Yang, S. C.; Zhu, J. B.; Lu, L. F.; Liang, B. W.; Yang, C. Z. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm. Res. 1999, 16, 751-757.
19. Yang, S. C.; Lu, L. F.; Cai, Y.; Zhu, J. B.; Liang, B. W.; Yang, C. Z. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Controlled Release 1999, 59, 299-307.
20. Seeballuck, F.; Ashford, M. B.; O'Driscoll, C. M. The effects of Pluronic block copolymers and Cremophor EL on intestinal lipoprotein processing and the potential link with P-glyco-protein in Caco-2 cells. Pharm. Res. 2003, 20, 1085-1092.
21. Alyautdin, R. N.; Petrov, V. E.; Langer, K.; Berthold, A.; Kharkevich D. A.; Kreuter, J. Delivery of loperamide across the blood-brain barrier with Polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm. Res. 1997, 14, 325-328.